PMID- 34226895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231108
IS  - 2688-2663 (Electronic)
IS  - 2688-2663 (Linking)
VI  - 2
IP  - 3
DP  - 2021 Sep
TI  - A bivalent recombinant vaccine targeting the S1 protein induces neutralizing 
      antibodies against both SARS-CoV-2 variants and wild-type of the virus.
PG  - 430-441
LID - 10.1002/mco2.72 [doi]
AB  - The emerging variants of severe acute respiratory syndrome coronavirus-2 
      (SARS-CoV-2) in pandemic call for the urgent development of universal corona 
      virus disease 2019 (COVID-19) vaccines which could be effective for both 
      wild-type SARS-CoV-2 and mutant strains. In the current study, we formulated 
      protein subunit vaccines with AS03 adjuvant and recombinant proteins of S1 
      subunit of SARS-CoV-2 (S1-WT) and S1 variant (K417N, E484K, N501Y, and D614G) 
      subunit (S1-Mut), and immunized transgenic mice that express human 
      angiotensin-converting enzyme 2 (hACE2). The S1 protein-specific antibody 
      production and the neutralization capability for SARS-CoV-2 and B.1.351 variant 
      were measured after immunization in mice. The results revealed that the S1-Mut 
      antigens were more effective in inhibiting the receptor-binding domain and ACE2 
      binding in B.1.351 variant than in wild-type SARS-CoV-2. Furthermore, the 
      development of a bivalent vaccine exhibited the ideal neutralization properties 
      against wild-type and B.1.351 variant, as well as other variants. Our findings 
      may provide a rationale for the development of a bivalent recombinant vaccine 
      targeting the S1 protein that can induce the neutralizing antibodies against both 
      SARS-CoV-2 variants and wild-type of the virus and may be of importance to 
      explore the potential clinical use of bivalent recombinant vaccine in the future.
CI  - (c) 2021 The Authors. MedComm published by Sichuan International Medical Exchange & 
      Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
FAU - He, Cai
AU  - He C
AUID- ORCID: 0000-0002-9959-1562
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Yang, Jingyun
AU  - Yang J
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - He, Xuemei
AU  - He X
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Hong, Weiqi
AU  - Hong W
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Lei, Hong
AU  - Lei H
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Chen, Zimin
AU  - Chen Z
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Shen, Guobo
AU  - Shen G
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Yang, Li
AU  - Yang L
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Li, Jiong
AU  - Li J
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Wang, Zhenling
AU  - Wang Z
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Song, Xiangrong
AU  - Song X
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
FAU - Wang, Wei
AU  - Wang W
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Lu, Guangwen
AU  - Lu G
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
FAU - Wei, Xiawei
AU  - Wei X
AUID- ORCID: 0000-0002-6513-6422
AD  - Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of 
      Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics 
      West China Hospital, Sichuan University Chengdu China.
AD  - WestVac Biopharma Co. Ltd. Chengdu China.
LA  - eng
PT  - Journal Article
DEP - 20210517
PL  - China
TA  - MedComm (2020)
JT  - MedComm
JID - 101769925
CIN - Signal Transduct Target Ther. 2021 Jul 17;6(1):278. PMID: 34274941
PMC - PMC8242662
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - bivalent vaccine
OT  - recombinant protein
OT  - variant
COIS- Guobo Shen, Li Yang, Jiong Li, Zhenling Wang, Wei Wang, Guangwen Lu, and Xiawei 
      Wei are employees of WestVac Biopharma Co. Ltd. This work was supported by 
      WestVac Biopharma Co. Ltd.
EDAT- 2021/07/07 06:00
MHDA- 2021/07/07 06:01
PMCR- 2021/05/17
CRDT- 2021/07/06 06:39
PHST- 2021/04/22 00:00 [received]
PHST- 2021/04/28 00:00 [revised]
PHST- 2021/04/28 00:00 [accepted]
PHST- 2021/07/07 06:00 [pubmed]
PHST- 2021/07/07 06:01 [medline]
PHST- 2021/07/06 06:39 [entrez]
PHST- 2021/05/17 00:00 [pmc-release]
AID - MCO272 [pii]
AID - 10.1002/mco2.72 [doi]
PST - epublish
SO  - MedComm (2020). 2021 May 17;2(3):430-441. doi: 10.1002/mco2.72. eCollection 2021 
      Sep.